SIMABS
Agoralaan, Abis Abis /
3590 Diepenbeek
BE
SIMABS
Foundation date
22/08/2019
Sector
#Biotechnology / R&D ServicesSubsector
- #Therapeutics - Biosimilars
- #Therapeutics - Nucleic acid drugs
- #Therapeutics - Proteins
- #R&D Services - Cell culture
- #R&D Services - CMO (Contract Manufacturing Organization)
- #R&D Services - Synthesis services
Therapeutic areas
SIMABS is a start-up biotechnology venture that wants to develop a new bio-manufacturing platform to provide cost effective therapeutic monoclonal antibodies at small scale to biopharmaceutical companies.
Upcoming events
All events-
2809 '22
NLSDays 2022
Event by: SwedenBIO -
2405 '22
PrecisionMed Expo & Summit
Event by: Smart Planet Media International -
2405 '22
EMERGE GHI
Event by: Smart Planet Media International
Latest news
More news-
Latest field trials validate strength of Biotalys’ first biocontrol Evoca
Thursday May 19th 2022
Read more
-
Belgian biotech in European Top-3 despite turbulent times
Wednesday May 18th 2022
Read more
-
KU Leuven announces collaboration and license agreement with Gilead Sciences for the development of new antivirals against the respiratory syncytial virus
Wednesday May 18th 2022
Read more